Deep in the shadowy corridors of laboratories and the silent pages of medical journals, secrets lie waiting to be uncovered—tales of ambition that soared too high to the sun, ideas that derailed progress, and innovations that should never have seen the light of day. This is—Crimes Against Innovation.

In this episode, Professor Russ Altman and Dr. Alistair Henry go head-to-head as they debate two major issues in healthcare innovation. Russ argues that rigid milestones in research hinder scientific creativity, while Alistair contends that over-resourcing stifles innovation. Host Nicola Hill decides which of these “crimes” deserves the title of the worst offender.

This podcast is produced and funded by UCB.

Hosted on Acast. See acast.com/privacy for more information.

Hosted on Acast. See acast.com/privacy for more information.

Hosted on Acast. See acast.com/privacy for more information.

In this episode, we tackle a transformative question: will traditional wet labs be rendered obsolete by digital and AI-powered innovations? Host Nicola Hill is joined by Professor Russ Altman from Stanford University, and Dr. Alistair Henry, UCB’s Chief Scientific Officer, to debate the rise of virtual pharmaceutical research.

Discover how technologies like machine learning, in silico compound screening, and digital twins are redefining drug discovery. From unprecedented advancements to persistent challenges, our experts dissect whether digital simulations can truly replicate—and surpass—the capabilities of physical labs. Will a hybrid model of digital and traditional methods shape the future of pharma research?

Hosted on Acast. See acast.com/privacy for more information.